A practical reference on PT-141: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-28. Anything still debated is marked as such rather than presented as settled.
Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.
Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.
Bremelanotide is a synthetic cyclic heptapeptide developed under the research code PT-141. The code reflects its position in an internal compound series rather than a chemical classification, and the name bremelanotide was later adopted for regulatory filings. Structurally it belongs to the melanocortin peptide family and shares a core sequence motif with alpha-melanocyte-stimulating hormone. The compound is supplied as an acetate salt in aqueous solution for injection. In reference literature it is indexed under both the code and the generic name, a dual listing that can complicate database searches.
Early work on melanocortin analogs in the 1980s and 1990s produced peptides intended to influence pigmentation and appetite. One of these, melanotan II, was observed to affect sexual desire as an incidental finding in self-administration reports. Researchers then pursued analogs with altered receptor selectivity and improved handling characteristics, and PT-141 emerged from that program in the late 1990s. The development path moved from dermatology and metabolism toward a central nervous system application, a shift that shaped both trial designs and the eventual label.
Regulatory review of bremelanotide concluded in 2019 with approval in the United States for a defined indication in premenopausal women. The reviewed formulation is a single-use prefilled autoinjector given subcutaneously, and its label carries cardiovascular monitoring language tied to blood pressure changes recorded during trials. Availability outside the approving jurisdiction varies, and in several countries the compound remains unapproved or is handled as a prescription-only item. Compounded and research-grade material also circulates, and it differs from the reviewed product in purity, characterization, and chain of custody.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Cyclic heptapeptide | Melanocortin receptor agonist |
| Molecular weight | Approximately 1025 Da | Calculated from the peptide sequence |
| Appearance | White to off-white powder | Common for lyophilized peptide preparations |
| Solubility | Soluble in water | Also soluble in polar organic solvents |
| Storage temperature | -20 °C or below | Used for long-term retention |
Bremelanotide is a synthetic cyclic heptapeptide that acts on a family of G-protein-coupled receptors. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous peptide associated with pigmentation and several central signalling pathways. A lactam bridge constrains the ring and slows enzymatic breakdown, which distinguishes it from the linear parent molecule. Research interest moved over time from pigment biology toward central nervous system effects, particularly circuits connected to sexual desire. Parenteral delivery is used because oral bioavailability is poor.
Early clinical work used an intranasal formulation, and later programmes switched to subcutaneous delivery for more consistent absorption. A subcutaneous product received regulatory approval in the United States in 2019 for premenopausal women with acquired, generalised hypoactive sexual desire disorder. Approval followed phase 3 trials in which active treatment separated from placebo on desire and distress measures, though the average difference was modest. Labeling carries a caution about transient blood pressure elevation, so cardiovascular history is assessed before prescribing. Questions about durability of benefit beyond several months remain open.
Routine characterisation of bremelanotide relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nm, where the peptide backbone absorbs. Mass spectrometry, typically in tandem mode with electrospray ionisation, confirms identity and supports quantification in biological matrices. Additional checks include amino acid analysis, peptide mapping after enzymatic digestion, and confirmation of the lactam bridge, since incomplete cyclisation produces a mass-shifted by-product. Purity values above 95 percent are common in reference-grade material, though reports vary in how strictly related substances are resolved from the parent peak.
The lyophilised solid is relatively stable when kept dry, protected from light and held at reduced temperature, commonly minus 20 degrees Celsius or lower for long-term storage. In solution the peptide is more vulnerable: tryptophan oxidation, hydrolysis of the lactam bridge and aggregation all become relevant over time, and the rate depends on pH, buffer composition and concentration. Repeated freeze-thaw cycles are generally avoided because they promote aggregation. Aqueous working solutions are typically prepared fresh or split into single-use aliquots to limit degradation before analysis.
Clinical programmes in this area have relied mainly on randomised, double-blind, placebo-controlled designs in premenopausal women. Primary endpoints usually combine a validated questionnaire covering desire domains with counts of satisfying sexual events and a separate measure of distress. Reported outcomes show statistically significant but modest average improvement over placebo, with wide individual variation. Adverse events such as nausea, flushing, and headache occur frequently and can limit tolerability. Whether short-term trial gains translate into lasting change for most users is an open question.
Evidence outside the studied population is sparse. Trials have concentrated on premenopausal women with a defined diagnosis, and data for postmenopausal women, men, and people taking interacting medications remain limited. Non-prescription use of the peptide for comparable goals is widespread but is not supported by published controlled data. Observed changes in blood pressure have drawn attention to cardiovascular monitoring during use. The literature generally frames the compound as a targeted receptor agonist rather than a general libido enhancer, and basic questions about mechanism and long-term safety are unresolved.
Lyophilised peptide is generally held below minus twenty degrees Celsius, protected from light and moisture, because hydrolysis and oxidation accumulate faster at ambient temperature. Once reconstituted, solutions are typically kept between two and eight degrees Celsius and used within a short window defined by the supplier. Repeated freeze-thaw cycles are avoided since they promote aggregation and loss of soluble material. Container material matters as well, because peptides adsorb to certain plastics and glass surfaces at low concentration. Stability figures supplied by a vendor apply only to the specific lot and buffer that were tested.
Identity and purity are usually established with reversed-phase high-performance liquid chromatography combined with mass spectrometry. A gradient of water and acetonitrile containing trifluoroacetic acid is a common mobile phase, and ultraviolet detection near 214 nanometres responds to the peptide backbone. Mass spectrometry confirms the expected molecular mass and helps reveal truncation or oxidation products. Purity is reported as a peak-area percentage, a figure that depends on the wavelength and gradient used, so values from different laboratories are not always directly comparable. Peptide mapping and amino acid analysis provide additional confirmation when required.
Regulatory status varies by jurisdiction, where approved prescription products, compounded preparations and research-grade material are treated as distinct categories with different documentation requirements. Suppliers of research material commonly issue a certificate of analysis listing purity, identity and sometimes endotoxin content. Independent verification by a third-party laboratory is often recommended because self-reported figures are difficult to check. Literature discussions usually state the source, purity and storage conditions of the material used, since these details affect reproducibility. Analysts note that a reported purity figure does not by itself describe biological activity.
== FDA testing == Before being released onto the U.S. market, Juvéderm was compared with Zyplast dermal filler, a bovine-based injectable facial filler made from collagen. In clinical studies conducted at several U.S. medical centers to evaluate safety and efficacy, or effectiveness, 146 subjects were followed for 24 weeks. The subjects had Juvéderm injected into one nasolabial fold and Zyplast in the other. Using scientific measuring scales, Juvéderm was deemed to provide a more persistent correction in the subjects’ facial folds. At the end of the study, the researchers asked subjects to judge which fold looked better to them. Eighty-eight percent chose the area treated with Juvéderm. Before FDA approval, two other clinical studies on Juvéderm were done on a total of 293 subjects in the United States. The safety profile and effectiveness was found to be similar to the first test.
A 1992 World Health Organization report described normal human semen as having a volume of 2 mL or greater, pH of 7.2 to 8.0, sperm concentration of 20×106 spermatozoa/mL or more, sperm count of 40×106 spermatozoa per ejaculate or more, and motility of 50% or more with forward progression (categories a and b) of 25% or more with rapid progression (category a) within 60 minutes of ejaculation. A 2005 review of the literature found that the average reported physical and chemical properties of human semen were as follows:
== Regulation == The regulation of the glyoxylate cycle involves carbon source availability, as it controls the transcriptional levels of key enzymes. Carbon catabolite repression is the main process that occurs in bacteria and fungi that regulates the transcriptional levels of the glyoxylate cycle, ensuring that the cycle is activated when glucose is not available. For instance, in Escherichia coli, the regulation of the isocitrate branch point takes place by regulating the transcription level of IclR and FadR, and through AceK, which is a bifunctional enzyme that acts as both a dehydrogenase kinase and a phosphatase. AceK is responsible for the regulation of isocitrate dehydrogenase and its switching roles in the citric acid cycle as well as the glyoxylate cycle. It determines whether the carbon atoms will be used in the glyoxylate cycle or the citric acid cycle. The phosphorylation, catalyzed by the AceK kinase function, of isocitrate dehydrogenase decreases its activity, and this phosphorylation can be reversed. In plants, the regulation of the glyoxylate cycle is achieved by regulating transcriptional levels during the seed germination process and through the mobilization of stored lipids . In bacteria, such as Mycobacterium tuberculosis, the glyoxylate cycle is up regulated especially when glucose is scarce and is needed during host infection. This regulation contributes to the growth and virulence of the pathogenic infection. Overall, these regulations allow for the conservation of carbon and activate the biosynthesis of key metabolites when carbon source is limited.
Sources: en.wikipedia.org
For the 2005 sequel The Ring Two, Chase was credited due to the use of archival footage from the first film, although actress Kelly Stables performed all the new on-screen material and motion capture for Samara. Between 2003 and 2004, Chase held a main cast role as Joyce, the quirky girlfriend of the title character, in the Fox period sitcom Oliver Beene. Her other notable credits during this period included the direct-to-video film Beethoven's 5th (2003) and the romantic comedy Carolina (2003), in which she played the younger version of Julia Stiles' character.
Particle-induced X-ray emission or proton-induced X-ray emission (PIXE) is a technique used for determining the elemental composition of a material or a sample. When a material is exposed to an ion beam, atomic interactions occur that give off EM radiation of wavelengths in the X-ray part of the electromagnetic spectrum specific to an element. PIXE is a powerful, yet non-destructive elemental analysis technique now used routinely by geologists, archaeologists, art conservators and others to help answer questions of provenance, dating and authenticity. The technique was first proposed in 1970 by Sven Johansson of Lund University, Sweden, and developed over the next few years with his colleagues Roland Akselsson and Thomas B Johansson. Recent extensions of PIXE using tightly focused beams (down to 1 μm) gives the additional capability of microscopic analysis. This technique, called microPIXE, can be used to determine the distribution of trace elements in a wide range of samples. A related technique, particle-induced gamma-ray emission (PIGE) can be used to detect some light elements. Additionally, there is a multiplexed instrument combining PIXE with mass spectrometry of molecules: PDI-PIXE-MS or PIXE-MS.
variation in the contents prior to packaging variation in the packaging components variation in the product and packaging processes variation in storage, distribution, cold chain, etc. variation in the quantity of contents
Sources: en.wikipedia.org
probe Any reagent used to make a single measurement in a biochemical assay such as a gene expression experiment. Molecules which have a specific affinity for one or more other molecules may be used to probe for the presence of those other molecules in samples of unknown composition. Probes are often labelled or otherwise used as reporters to indicate whether or not a specific chemical reaction is taking place. See also hybridization probe.
== Principle == The protein binding principles in EBA are the same as in classical column chromatography and the common ion-exchange, hydrophobic interaction and affinity chromatography ligands can be used. After the adsorption step is complete, the fluidized bed is washed to flush out any remaining particulates. Elution of the adsorbed proteins was commonly performed with the eluent flow in the reverse direction; that is, as a conventional packed bed, in order to recover the adsorbed solutes in a smaller volume of eluent. However, a new generation of EBA columns has been developed, which maintain the bed in the expanded state during this phase, producing high-purity, high yields of e.g. MAbs [monoclonal antibodies] in even smaller volumes of eluent. Process duration at manufacturing scale has also been cut considerably (under 7 hours in some cases). EBA may be considered to combine both the "Removal of Insolubles" and the "Isolation" steps of the 4-step downstream processing heuristic. The major limitations associated with EBA technology is biomass interactions and aggregations onto adsorbent during processing. Where classical column chromatography uses a solid phase made by a packed bed, EBA uses particles in a fluidized state, ideally expanded by a factor of 2. Expanded bed adsorption is, however, different from fluidised bed chromatography in essentially two ways: one, the EBA resin contains particles of varying size and density which results in a gradient of particle size when expanded; and two, when the bed is in its expanded state, local loops are formed.
The headquarters of the Swiss charity Mine Action FSD, in Kharkiv, was struck by a Russian ballistic missile. The Ukrainian 79th Tavrian Air Assault Brigade claimed to have repelled a major Russian assault on Kurakhove, inflicting losses of 12 motorcycles destroyed, six tanks and seven armoured vehicles damaged, 40 Russian soldiers killed and 37 others injured. Ukrainian media reported that the HUR carried out a cyberattack on several banks operating in Russia and other financial institutions in the country. Ukrainian soldiers of the "Khortytsia" group, based in Kharkiv, shot other Ukrainian soldiers due to "personal" issues, killing three soldiers and wounding four. A GRU officer and his wife were injured in a car bombing in Moscow. The Ukrainians claimed that Russian losses in Vovchansk include the 138th Separate Guards Motor Rifle Brigade, the 83rd Tank Regiment and the 157th Tank Regiment. According to Vitaly Sarantsev, spokesman for Ukraine’s operational-tactical group Kharkiv, "the staff number of motorized rifle brigades in the Russian Federation is up to 5,000 personnel, and tank regiments have 94 units of equipment (tanks)". He claimed that Russian losses (killed, wounded, or captured) for "roughly a division's worth of personnel" were 91 percent.
Sources: en.wikipedia.org
PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.
PDE5 inhibitors act on peripheral vascular tissue to increase blood flow. Bremelanotide acts centrally on melanocortin receptors and is associated with dopaminergic pathways. The two approaches therefore target different parts of the arousal response.
It is a synthetic peptide analog rather than a hormone produced by the body. Alpha-melanocyte-stimulating hormone is the natural peptide it resembles. The two share structural features but are distinct molecules.
PT-141 was the internal development code assigned to bremelanotide during preclinical research. Reference sources sometimes index the peptide under the code rather than the generic name. The two terms describe the same molecule.